Immuron Shares spike on FDA approval for Travelan IND application
- Immuron’s (IMC) lands US Food and Drug Administration (FDA) approval for its investigational new drug application for its Travelan product
- With the approval in hand, IMC can proceed with its clinical trial assessing the safety and efficacy of the drug to prevent infectious diarrhea
- The company plans to enrol up to 60 healthy adults in the study, with half to receive a once-daily dose of 1200 milligrams of Travelan and half to receive a placebo
- Recruitment is due to begin in the first half of the new year, with headline results from the trial expected to be reported by the end of 2023
- The company shares are up 23.61 per cent and trading at 8.9 cents at 11:56 am AEDT
